ADMS Adamas Pharmaceuticals Inc.

3.98
-0.02  -1%
Previous Close 4
Open 3.97
Price To Book 2.58
Market Cap 110,529,038
Shares 27,771,115
Volume 313,761
Short Ratio
Av. Daily Volume 644,832
Stock charts supplied by TradingView

NewsSee all news

  1. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option

  2. Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference

    EMERYVILLE, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders,

  3. Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson's Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress

    EMERYVILLE, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS)

  4. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted its new Chief Executive

  5. Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer

    - Gregory Went, Ph.D., Founder, transitions to a strategic advisory role - David Mahoney, lead independent director, appointed to Chairman of the Board EMERYVILLE, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) --

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Further development deferred - noted May 9, 2019.
ADS-4101
Partial onset seizures in patents with epilepsy
Phase 3 data due 4Q 2019.
GOCOVRI (amantadine)
Multiple sclerosis (MS)
Approved December, 24 2014.
Namzaric
Moderate to severe dementia of the Alzheimer's type.
Approval announced August 24, 2017.
ADS-5102
Levodopa-Induced Dyskinesia
Phase 3 open-label data released April 19, 2018.
GOCOVRI (amantadine)
Dyskinesia patients with Parkinson's disease

Latest News

  1. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option

  2. Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference

    EMERYVILLE, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders,

  3. Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson's Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress

    EMERYVILLE, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS)

  4. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted its new Chief Executive

  5. Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer

    - Gregory Went, Ph.D., Founder, transitions to a strategic advisory role - David Mahoney, lead independent director, appointed to Chairman of the Board EMERYVILLE, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) --

  6. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted four new employees the